{"id":"W4406870016","doi":"10.1200/jco.2025.43.4_suppl.135","title":"Phase Ib study of gevokizumab (GEVO) in combination with standard-of-care (SoC) anticancer therapies in patients (pts) with metastatic colorectal cancer (mCRC), metastatic gastroesophageal cancer (mGEC), and metastatic renal cell cancer (mRCC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Colorectal cancer; Oncology; Internal medicine; Cancer; Standard of care; Renal cell carcinoma; Phases of clinical research; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00127946,0.001138305,0.001929555,0.0004707398,0.0003650593,0.001383546,0.0008467367,0.0009798281,0.00252823],"category_scores_gemma":[0.00074581,0.0007005339,0.001373653,0.0004770865,0.0009164443,0.0008992823,0.0003566675,0.00305809,0.0007972509],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001445564,"about_ca_system_score_gemma":0.001958233,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00144616,"about_ca_topic_score_gemma":0.003729502,"domain_scores_codex":[0.9995689,0.0001678328,0.00002485306,0.00009394709,0.0000431342,0.0001013429],"domain_scores_gemma":[0.9992143,0.00007833846,0.000142188,0.00005293911,0.00004348548,0.0004686642],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8023077,0.09447357,0.007759801,0.0006721125,0.001349161,0.0001702957,0.0002144925,0.001564095,0.03955898,0.0002520379,0.002455083,0.04922269],"study_design_scores_gemma":[0.4028816,0.5801558,0.00974793,0.00003614423,0.0004711216,0.0001996334,0.00006056998,0.0009648823,0.003128915,0.0001402032,0.002188938,0.0000242741],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930165,0.001644898,0.0004810106,0.00027073,0.0001190394,0.00206851,0.0009284383,0.00008122312,0.00138968],"genre_scores_gemma":[0.9927858,0.001049456,0.001197288,0.0005219112,0.0001170959,0.00142237,0.001746272,0.00001849785,0.001141407],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00252823,"threshold_uncertainty_score":0.01048833,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04286997239890329,"score_gpt":0.4337288784768514,"score_spread":0.3908589060779481,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}